Search

Your search keyword '"Al-Hajj, Muhammad"' showing total 36 results
Start Over Author "Al-Hajj, Muhammad"
36 results on '"Al-Hajj, Muhammad"'

2. Prevalence and determinants of herbal medicine use among adults attending the national health insurance clinic of abubakar tafawa balewa university teaching hospital, Bauchi, Nigeria

Author

Afisulahi Abiodun Maiyegun, Yahkub Babatunde Mutalub, Attahiru Al-Hajj Muhammad, and Mark Divine Akangoziri

Subjects
cross-sectional studies, herbal medicine, national health insurance, nigeria, Medicine
Abstract

Background: The use of complementary and alternative medicine (CAM) is growing worldwide, with herbal medicine often the most common CAM, especially in Sub-Saharan Africa. For optimal patient care, the clinician should know what other medications patients use and why. While many studies have been done on herbal medicine use in the general population, studies on this topic among insured patients in Nigeria are scanty, at best. Thus, there is a need for more researches in this area. Aim: This study aimed to assess the use of herbal medicine among patients enrolled in the National Health Insurance Scheme (NHIS). Patients, Materials and Methods: The participants were adult patients (at least 18 years old), of both genders, attending the NHIS Clinic of Abubakar Tafawa Balewa University Teaching Hospital, Bauchi. This was an analytical, cross-sectional study. Participants were selected by systematic random sampling. Very sick patients and those who refused to grant consent to the study were exempted. Only seven declined, giving a response rate of 98.1% (364/371). An interviewer-administered questionnaire was used to collect information on participants' biodata and the use of herbal medicine. The study was done from October 1, 2020 to December 23, 2020 over 12 weeks. Results: The lifetime prevalence of herbal medicine use was 76.65%. The most common herbs used were moringa (47.31%), garlic (46.95%), ginger (38.71%), lemon (36.20%), and black seed (33.69%). Most of the participants (67.4%) used herbs for treatment, and the main reason for use was their effectiveness (61.3%). Over a third of participants combined herbs and orthodox medicine, and 82.44% never told their doctors they used herbs. Marital status of the study participants was the only variable associated with herbal medicine use (P = 0.022 at 95% confidence level). Conclusion: Patients in the NHIS use herbal medicine, though the point prevalence is relatively lower than in uninsured patients. Hence, doctors should be careful to enquire about the herbs these patients use and counsel them appropriately.

Published
2022
Full Text
View/download PDF

3. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial

Author

Cordoba, Shaun, Onuoha, Shimobi, Thomas, Simon, Pignataro, Daniela Soriano, Hough, Rachael, Ghorashian, Sara, Vora, Ajay, Bonney, Denise, Veys, Paul, Rao, Kanchan, Lucchini, Giovanna, Chiesa, Robert, Chu, Jan, Clark, Liz, Fung, Mei Mei, Smith, Koval, Peticone, Carlotta, Al-Hajj, Muhammad, Baldan, Vania, Ferrari, Mathieu, Srivastava, Saket, Jha, Ram, Arce Vargas, Frederick, Duffy, Kevin, Day, William, Virgo, Paul, Wheeler, Lucy, Hancock, Jeremy, Farzaneh, Farzin, Domning, Sabine, Zhang, Yiyun, Khokhar, Nushmia Z., Peddareddigari, Vijay G. R., Wynn, Robert, Pule, Martin, and Amrolia, Persis J.

Published
2021
Full Text
View/download PDF

5. Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy

Author

Lee, Lydia, primary, Lim, Wen Chean, additional, Galas-Filipowicz, Daria, additional, Fung, Kent, additional, Taylor, Julia, additional, Patel, Dominic, additional, Akbar, Zulaikha, additional, Alvarez Mediavilla, Elena, additional, Wawrzyniecka, Patrycja, additional, Shome, Debarati, additional, Reijmers, Rogier M, additional, Gregg, Trillian, additional, Wood, Leigh, additional, Day, William, additional, Cerec, Virginie, additional, Ferrari, Mathieu, additional, Thomas, Simon, additional, Cordoba, Shaun, additional, Onuoha, Shimobi, additional, Khokhar, Nushmia, additional, Peddareddigari, Vijay, additional, Al-Hajj, Muhammad, additional, Cavet, Jim, additional, Zweegman, Sonja, additional, Rodriguez-Justo, Manuel, additional, Yong, Kwee, additional, Pule, Martin, additional, and Popat, Rakesh, additional

Published
2023
Full Text
View/download PDF

7. Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy

Author

Lee, Lydia, Lim, Wen Chean, Galas-Filipowicz, Daria, Fung, Kent, Taylor, Julia, Patel, Dominic, Akbar, Zulaikha, Alvarez Mediavilla, Elena, Wawrzyniecka, Patrycja, Shome, Debarati, Reijmers, Rogier M., Gregg, Trillian, Wood, Leigh, Day, William, Cerec, Virginie, Ferrari, Mathieu, Thomas, Simon, Cordoba, Shaun, Onuoha, Shimobi, Khokhar, Nushmia, Peddareddigari, Vijay, Al-Hajj, Muhammad, Cavet, Jim, Zweegman, Sonja, Rodriguez-Justo, Manuel, Youg, Kwee, Pule, Martin, and Popat, Rakesh

Abstract

BACKGROUND: We used a proliferating ligand (APRIL) to construct a ligand-based third generation chimeric antigen receptor (CAR) able to target two myeloma antigens, B-cell maturation antigen (BCMA) and transmembrane activator and CAML interactor. METHODS: The APRIL CAR was evaluated in a Phase 1 clinical trial (NCT03287804, AUTO2) in patients with relapsed, refractory multiple myeloma. Eleven patients received 13 doses, the first 15×106 CARs, and subsequent patients received 75,225,600 and 900×106 CARs in a 3+3 escalation design. RESULTS: The APRIL CAR was well tolerated. Five (45.5%) patients developed Grade 1 cytokine release syndrome and there was no neurotoxicity. However, responses were only observed in 45.5% patients (1×very good partial response, 3×partial response, 1×minimal response). Exploring the mechanistic basis for poor responses, we then compared the APRIL CAR to two other BCMA CARs in a series of in vitro assays, observing reduced interleukin-2 secretion and lack of sustained tumor control by APRIL CAR regardless of transduction method or co-stimulatory domain. There was also impaired interferon signaling of APRIL CAR and no evidence of autoactivation. Thus focusing on APRIL itself, we confirmed similar affinity to BCMA and protein stability in comparison to BCMA CAR binders but reduced binding by cell-expressed APRIL to soluble BCMA and reduced avidity to tumor cells. This indicated either suboptimal folding or stability of membrane-bound APRIL attenuating CAR activation. CONCLUSIONS: The APRIL CAR was well tolerated, but the clinical responses observed in AUTO2 were disappointing. Subsequently, when comparing the APRIL CAR to other BCMA CARs, we observed in vitro functional deficiencies due to reduced target binding by cell-expressed ligand.

Published
2023

8. Supplementary Figure 1 and Table 1 from Novel Bispecific Domain Antibody to LRP6 Inhibits Wnt and R-spondin Ligand-Induced Wnt Signaling and Tumor Growth

Author

Jackson, Heather, primary, Granger, David, primary, Jones, Gavin, primary, Anderson, Louisa, primary, Friel, Sarah, primary, Rycroft, Daniel, primary, Fieles, William, primary, Tunstead, James, primary, Steward, Michael, primary, Wattam, Trevor, primary, Walker, Adam, primary, Griggs, Jeremy, primary, Al-Hajj, Muhammad, primary, and Shelton, Christopher, primary

Published
2023
Full Text
View/download PDF

9. Data from Novel Bispecific Domain Antibody to LRP6 Inhibits Wnt and R-spondin Ligand-Induced Wnt Signaling and Tumor Growth

Author

Jackson, Heather, primary, Granger, David, primary, Jones, Gavin, primary, Anderson, Louisa, primary, Friel, Sarah, primary, Rycroft, Daniel, primary, Fieles, William, primary, Tunstead, James, primary, Steward, Michael, primary, Wattam, Trevor, primary, Walker, Adam, primary, Griggs, Jeremy, primary, Al-Hajj, Muhammad, primary, and Shelton, Christopher, primary

Published
2023
Full Text
View/download PDF

10. Supplemental Figure Legend from Novel Bispecific Domain Antibody to LRP6 Inhibits Wnt and R-spondin Ligand-Induced Wnt Signaling and Tumor Growth

Author

Jackson, Heather, primary, Granger, David, primary, Jones, Gavin, primary, Anderson, Louisa, primary, Friel, Sarah, primary, Rycroft, Daniel, primary, Fieles, William, primary, Tunstead, James, primary, Steward, Michael, primary, Wattam, Trevor, primary, Walker, Adam, primary, Griggs, Jeremy, primary, Al-Hajj, Muhammad, primary, and Shelton, Christopher, primary

Published
2023
Full Text
View/download PDF

13. In Vivo RNAi Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling

Author

Miller, Peter G., Al-Shahrour, Fatima, Hartwell, Kimberly A., Chu, Lisa P., Järås, Marcus, Puram, Rishi V., Puissant, Alexandre, Callahan, Kevin P., Ashton, John, McConkey, Marie E., Poveromo, Luke P., Cowley, Glenn S., Kharas, Michael G., Labelle, Myriam, Shterental, Sebastian, Fujisaki, Joji, Silberstein, Lev, Alexe, Gabriela, Al-Hajj, Muhammad A., Shelton, Christopher A., Armstrong, Scott A., Root, David E., Scadden, David T., Hynes, Richard O., Mukherjee, Siddhartha, Stegmaier, Kimberly, Jordan, Craig T., and Ebert, Benjamin L.

Published
2013
Full Text
View/download PDF

16. Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma

Author

Straathof, Karin, primary, Flutter, Barry, additional, Wallace, Rebecca, additional, Jain, Neha, additional, Loka, Thalia, additional, Depani, Sarita, additional, Wright, Gary, additional, Thomas, Simon, additional, Cheung, Gordon Weng-Kit, additional, Gileadi, Talia, additional, Stafford, Sian, additional, Kokalaki, Evangelia, additional, Barton, Jack, additional, Marriott, Clare, additional, Rampling, Dyanne, additional, Ogunbiyi, Olumide, additional, Akarca, Ayse U., additional, Marafioti, Teresa, additional, Inglott, Sarah, additional, Gilmour, Kimberly, additional, Al-Hajj, Muhammad, additional, Day, William, additional, McHugh, Kieran, additional, Biassoni, Lorenzo, additional, Sizer, Natalie, additional, Barton, Claire, additional, Edwards, David, additional, Dragoni, Ilaria, additional, Silvester, Julie, additional, Dyer, Karen, additional, Traub, Stephanie, additional, Elson, Lily, additional, Brook, Sue, additional, Westwood, Nigel, additional, Robson, Lesley, additional, Bedi, Ami, additional, Howe, Karen, additional, Barry, Ailish, additional, Duncan, Catriona, additional, Barone, Giuseppe, additional, Pule, Martin, additional, and Anderson, John, additional

Published
2020
Full Text
View/download PDF

18. Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL.

Author

Osborne, Wendy, primary, Marzolini, Maria, additional, Tholouli, Eleni, additional, Ramakrishnan, Aravind, additional, Bachier, Carlos R., additional, McSweeney, Peter A, additional, Irvine, David, additional, Zhang, Michael, additional, Al-Hajj, Muhammad Ali, additional, Pule, Martin, additional, Thomas, Simon, additional, Jonnaert, Maud, additional, Peddareddigari, Vijay Gopal Reddy, additional, Khokhar, Nushmia Z., additional, Chen, Robert W., additional, and Ardeshna, Kirit, additional

Published
2020
Full Text
View/download PDF

19. Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Popat, Rakesh, primary, Zweegman, Sonja, additional, Cavet, Jim, additional, Yong, Kwee, additional, Lee, Lydia, additional, Faulkner, Jim, additional, Kotsopoulou, Ekaterini, additional, Al-Hajj, Muhammad, additional, Thomas, Simon, additional, Cordoba, Shaun P, additional, Pule, Martin, additional, Cerec, Virginie, additional, Peddareddigari, Vijay G R, additional, Khokhar, Nushmia Z, additional, and Menne, Tobias F, additional

Published
2019
Full Text
View/download PDF

20. Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study

Author

Ardeshna, Kirit M., primary, Marzolini, Maria A V, primary, Norman, Jane, primary, Al-Hajj, Muhammad, primary, Thomas, Simon, primary, Faulkner, Jim, primary, Kotsopoulou, Ekaterini, primary, Pule, Martin, primary, Peddareddigari, Vijay G R, primary, Khokhar, Nushmia Z, primary, Jonnaert, Maud, primary, Chen, Robert, primary, and Osborne, Wendy, primary

Published
2019
Full Text
View/download PDF

21. Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study

Author

Amrolia, Persis J, primary, Wynn, Robert, additional, Hough, Rachael E, additional, Vora, Ajay, additional, Bonney, Denise, additional, Veys, Paul, additional, Chiesa, Robert, additional, Rao, Kanchan, additional, Clark, Liz, additional, Al-Hajj, Muhammad, additional, Cordoba, Shaun P, additional, Onuoha, Shimobi, additional, Kotsopoulou, Ekaterini, additional, Khokhar, Nushmia Z, additional, Pule, Martin, additional, and Peddareddigari, Vijay G R, additional

Published
2019
Full Text
View/download PDF

22. Simultaneous Targeting of CD19 and CD22: Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study

Author

Amrolia, Persis J, primary, Wynn, Robert, additional, Hough, Rachael, additional, Vora, Ajay, additional, Bonney, Denise, additional, Veys, Paul, additional, Rao, Kanchan, additional, Chiesa, Robert, additional, Al-Hajj, Muhammad, additional, Cordoba, Shaun P, additional, Onuoha, Shimobi, additional, Kotsopoulou, Ekaterini, additional, Khokhar, Nushmia Z, additional, Pule, Martin, additional, and Peddareddigari, Vijay G R, additional

Published
2018
Full Text
View/download PDF

23. Study of AUTO3, the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22, Followed By Anti-PD1 Consolidation in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Alexander Study

Author

Ardeshna, Kirit, primary, Marzolini, Maria A V, additional, Osborne, Wendy, additional, Al-Hajj, Muhammad, additional, Thomas, Simon, additional, Faulkner, Jim, additional, Pule, Martin, additional, Peddareddigari, Vijay G R, additional, and Khokhar, Nushmia Z, additional

Published
2018
Full Text
View/download PDF

24. Novel Bispecific Domain Antibody to LRP6 Inhibits Wnt and R-spondin Ligand-Induced Wnt Signaling and Tumor Growth

Author

Jackson, Heather, primary, Granger, David, additional, Jones, Gavin, additional, Anderson, Louisa, additional, Friel, Sarah, additional, Rycroft, Daniel, additional, Fieles, William, additional, Tunstead, James, additional, Steward, Michael, additional, Wattam, Trevor, additional, Walker, Adam, additional, Griggs, Jeremy, additional, Al-Hajj, Muhammad, additional, and Shelton, Christopher, additional

Published
2016
Full Text
View/download PDF

25. In Vivo RNAi Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling

Author

Massachusetts Institute of Technology. Department of Biology, Koch Institute for Integrative Cancer Research at MIT, Hynes, Richard O., Labelle, Myriam, Miller, Peter G., Al-Shahrour, Fatima, Hartwell, Kimberly A., Chu, Lisa P., Jaras, Marcus, Puram, Rishi V., Puissant, Alexandre, Callahan, Kevin P., Ashton, John, McConkey, Marie, Poveromo, Luke P., Cowley, Glenn S., Kharas, Michael G., Shterental, Sebastian, Fujisaki, Joji, Silberstein, Lev, Alexe, Gabriela, Al-Hajj, Muhammad A., Shelton, Christopher A., Armstrong, Scott A., Root, David E., Scadden, David T., Mukherjee, Siddhartha, Stegmaier, Kimberly, Jordan, Craig T., Ebert, Benjamin L., Hynes, Richard O, Massachusetts Institute of Technology. Department of Biology, Koch Institute for Integrative Cancer Research at MIT, Hynes, Richard O., Labelle, Myriam, Miller, Peter G., Al-Shahrour, Fatima, Hartwell, Kimberly A., Chu, Lisa P., Jaras, Marcus, Puram, Rishi V., Puissant, Alexandre, Callahan, Kevin P., Ashton, John, McConkey, Marie, Poveromo, Luke P., Cowley, Glenn S., Kharas, Michael G., Shterental, Sebastian, Fujisaki, Joji, Silberstein, Lev, Alexe, Gabriela, Al-Hajj, Muhammad A., Shelton, Christopher A., Armstrong, Scott A., Root, David E., Scadden, David T., Mukherjee, Siddhartha, Stegmaier, Kimberly, Jordan, Craig T., Ebert, Benjamin L., and Hynes, Richard O

Abstract

We used an in vivo small hairpin RNA (shRNA) screening approach to identify genes that are essential for MLL-AF9 acute myeloid leukemia (AML). We found that Integrin Beta 3 (Itgb3) is essential for murine leukemia cells in vivo and for human leukemia cells in xenotransplantation studies. In leukemia cells, Itgb3 knockdown impaired homing, downregulated LSC transcriptional programs, and induced differentiation via the intracellular kinase Syk. In contrast, loss of Itgb3 in normal hematopoietic stem and progenitor cells did not affect engraftment, reconstitution, or differentiation. Finally, using an Itgb3 knockout mouse model, we confirmed that Itgb3 is dispensable for normal hematopoiesis but is required for leukemogenesis. Our results establish the significance of the Itgb3 signaling pathway as a potential therapeutic target in AML., National Institutes of Health (U.S.) (Harvard Stem Cell Institute. GlaxoSmithKline. Grant P01 CA108631), National Institutes of Health (U.S.) (Harvard Stem Cell Institute. GlaxoSmithKline. Grant RC1 CA145229), National Institutes of Health (U.S.) (Harvard Stem Cell Institute. GlaxoSmithKline. Grant R01 CA140292), National Institutes of Health (U.S.) (Harvard Stem Cell Institute. GlaxoSmithKline. Grant CA148180)

Published
2015

31. In Vivo RNA Interference Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling

Author

Al-Shahrour, Fatima, Hartwell, Kimberly A., Chu, Lisa P, Marcus, Jaras, Puram, Rishi V, Puissant, Alexandre, Callahan, Kevin, Ashton, John M, McConkey, Marie Ellen, Poveromo, Luke, Cowley, Glenn, Kharas, Michael G, Labelle, Myriam, Shterental, Sebastian, Al-Hajj, Muhammad, Shelton, Christopher, Armstrong, Scott A., Root, David E., Hynes, Richard, Mukherjee, Siddhartha, Stegmaier, Kimberly, Jordan, Craig T., and Ebert, Benjamin L.

Published
2011
Full Text
View/download PDF

32. Spectrum.

Author

Ansari, Iqbal A., Kuroda, Toshio Hisham, Hasan, YusufFadl, Martin, B. G., Severi, Dimitri, Braibanti, Ralph, Ansari, Ghaus, Schermerhorn, R. A., Soghayroun, Ibrahim El Zein, Wright, Theodore P., Bowers, Stephen R., Bennigsen, Alexandre, Mohammad, Shan, Syeed, Sayyid Mohammad, Haight, Bruce M., Meenai, S. A., Al-Hajj, Muhammad Ahmad, Diller, Anthony, and Hamdani, Daood Hassan

Published
1980
Full Text
View/download PDF

33. Spectrum

Author

Ansari, Iqbal, Kuroda, Toshio Hisham, Hasan, YusufFadl, Martin, B. G., Severi, Dimitri, Braibanti, Ralph, Ansari, Ghaus, Schermerhorn, R. A., Soghayroun, Ibrahim El Zein, Wright, Theodore, Bowers, Stephen, Bennigsen, Alexandre, Mohammad, Shan, Syeed, Sayyid Mohammad, Haight, Bruce, Meenai, S. A., Al-Hajj, Muhammad Ahmad, Diller, Anthony, and Hamdani, Daood Hassan

Published
1980
Full Text
View/download PDF

34. International Liability for Damages Caused by Satellites and other Space Vehicles in light of Outer Space Treaties

Author

Al-Hajj, Muhammad Ali and Al-Hajj, Muhammad Ali

Abstract

The research aims to describe the provisions of international liability of the damage caused by satellites and other spacecraft as well as addressing the definition of outer space and its nature. Then, it covers the role of the United Nations (UN) in its organization through adoption of several resolutions and agreements detailing the provisions that are relevant to the registration of launched vehicles into space and the rules of liability resulting from damages that may be caused. In conclusion, the study holds that states bear an absolute liability when damages occur on the ground or while the aircraft is in the air or by applying fault-based approach in the other cases. Consequently, there are several flaws in the liability system, most notably the absence of mandatory and effective dispute settlement mechanisms and the failure to extend compensation for all affected entities.

35. In VivoRNA Interference Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling

Author

Al-Shahrour, Fatima, Hartwell, Kimberly A., Chu, Lisa P, Marcus, Jaras, Puram, Rishi V, Puissant, Alexandre, Callahan, Kevin, Ashton, John M, McConkey, Marie Ellen, Poveromo, Luke, Cowley, Glenn, Kharas, Michael G, Labelle, Myriam, Shterental, Sebastian, Al-Hajj, Muhammad, Shelton, Christopher, Armstrong, Scott A., Root, David E., Hynes, Richard, Mukherjee, Siddhartha, Stegmaier, Kimberly, Jordan, Craig T., and Ebert, Benjamin L.

Abstract

Abstract 758

Published
2011
Full Text
View/download PDF

36. The ABCs of cancer stem cell drug resistance.

Author

Elliott A, Adams J, and Al-Hajj M

Subjects
ATP-Binding Cassette Transporters antagonists & inhibitors, Antineoplastic Agents pharmacokinetics, Biological Transport, Drug Resistance, Multiple drug effects, Drug Resistance, Neoplasm drug effects, Humans, Neoplasms genetics, Neoplastic Stem Cells metabolism, ATP-Binding Cassette Transporters genetics, Antineoplastic Agents pharmacology, Neoplasms drug therapy
Abstract

Chemotherapy is generally effective as a non-targeted therapy in killing the majority of cells in a tumor; however, a small population of residual cells that are intrinsically resistant to such agents persist after chemotherapy, ultimately resulting in patient relapse. There is evidence that these cells within resistant tumors are cancer stem cells. A common mechanism of multidrug resistance used by residual tumor cells involves the expression of the ATP-binding cassette (ABC) transporters. Understanding the anticancer drug transport properties of these transporters, as well as their physiological functions, in addition to improved efforts to discover and characterize selective inhibitors, will lead to more effective therapeutics for oncology.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results